Home-Based tDCS Treatment Of Major Depressive Disorder
Safety And Efficacy of Remotely Supervised Home-Based tDCS Treatment Of Major Depressive Disorder
Sooma Medical Inc
200 participants
Jun 27, 2025
INTERVENTIONAL
Conditions
Summary
The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
In tDCS treatment session electrical current (2 mA) is applied for 30 minutes through two electrodes placed on top of scalp to modulate neural activity.
Sham treatment mimics the active device use and the experiences from the active stimulation while minimizing active effects.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06976697